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Hepatitis C virus (HCV) is a single-strandedRNA virus
encoding a single polyprotein whose translation is
driven by an internal ribosome entry site (IRES).
HCV infection strongly induces antiviral interferon-
stimulated gene (ISG) expression in the liver, yet it
persists, suggesting that HCV can block ISG effector
function. We now show that HCV infection triggers
phosphorylation and activation of the RNA-depen-
dent protein kinase PKR, which inhibits eukaryotic
translation initiation factor eIF2a and attenuates
ISG protein expression despite normal ISG mRNA
induction. ISG protein induction is restored and the
antiviral effects of interferon are enhanced when
PKR expression is suppressed in interferon-treated
infected cells. Whereas host protein translation,
including antiviral ISGs, is suppressed by activated
PKR, HCV IRES-dependent translation is not. These
results suggest that the ability of HCV to activate
PKR may, paradoxically, be advantageous for the
virus during an IFN response by preferentially sup-
pressing the translation of ISGs.
INTRODUCTION
Hepatitis C virus (HCV) is a major human pathogen. More than
170 million people are chronically infected, many of whom will
develop chronic liver disease and hepatocellular carcinoma
(Alter and Seeff, 2000). There is no vaccine against HCV, and
the most widely used therapy, type I interferon (IFN) combined
with ribavirin, is successful in only a fraction of chronically
infected patients and has toxic side effects (Patel and McHutch-
ison, 2004).
HCV, the sole member of genusHepaciviruswithin the Flavivir-
idae family (Maniloff, 1995), is an enveloped, single-stranded,
positive-sense RNA virus (Choo et al., 1991). The HCV genome
contains a long open reading frame (ORF) that encodes a single
polyprotein of3000 amino acids (Choo et al., 1991). The ORF is
flanked by 50 and 30 nontranslated regions (NTR) that contain
essential sequences for RNA translation and replication (Friebe
et al., 2001, 2005; Honda et al., 1999). Polyprotein translation
is driven by a highly structured internal ribosome entry site
(IRES) located in the 50 NTR (Honda et al., 1999). The polyproteinCell Host &is co- and posttranslationally processed by cellular and viral
proteases, leading to the expression of the structural (core, E1,
and E2) and nonstructural proteins (p7, NS2, NS3, NS4A,
NS4B, NS5A, and NS5B) (Penin et al., 2004).
Type I interferons (IFNa/b) are produced in response to many
virus infections, and they induce a variety of IFN-stimulated
genes (ISGs) (Goodbourn et al., 2000), some of which have anti-
viral activity (Samuel, 2001). Using the recently developed HCV
JFH1 in vitro infection system (Lindenbach et al., 2005; Wakita
et al., 2005; Zhong et al., 2005), we and others have shown
that HCV efficiently blocks double-stranded RNA signaling by
NS3/4A-dependent and -independent mechanisms (Cheng
et al., 2006; Foy et al., 2005; Li et al., 2005), thereby preventing
the production of type I IFN by the infected cell. Nevertheless,
in vivo studies in experimentally infected chimpanzees (Hoofna-
gle, 2002; Su et al., 2002) and naturally HCV-infected humans
(Alter and Seeff, 2000) have demonstrated that HCV infection
strongly induces the expression of ISG mRNAs in the liver.
However, HCV persists in the liver despite the induction of these
ISGs (Alter and Seeff, 2000), raising the possibility that HCV can
block the effector function of the ISGs in the infected cells.
The mechanisms underlying HCV resistance to IFN are not
well understood. Previous attempts to answer these questions
used systems, e.g., subgenomic replicons and viral protein
overexpression, that reproduce only isolated aspects of the
HCV viral cycle. Nonetheless, these studies yielded a list of
candidate resistance mechanisms, including inhibition of Jak-
STAT signaling by several HCV proteins, induction of interleukin
8 expression by NS5A, induction of SOCS-3 signaling by HCV
core protein, transcriptional suppression of ISGs by HCV core
protein, and repression of PKR protein kinase by HCV NS5A
and E2 proteins and by the IRES element of HCV (reviewed in
Wohnsland et al., 2007).
The recently developed HCV cell culture infection system
(Lindenbach et al., 2005; Wakita et al., 2005; Zhong et al.,
2005) permits analysis of all of the steps in the HCV life cycle,
including its IFN resistance mechanisms, in a more physiological
context. In this study, we tested the hypothesis that HCV evades
the antiviral effect of IFN by blocking its effector functions down-
stream of the ISG mRNAs. We discovered that, although HCV
does not block the IFN-induced ISG mRNA transcription, it
strongly suppresses ISG protein expression and global cellular
protein synthesis at the same time that it strongly induces the
phosphorylation of PKR and eIF2a. Importantly, ISG protein
expression is restored, and the antiviral effect of IFN is enhanced
in PKR-downregulated cells, suggesting that, by inducing PKRMicrobe 6, 513–522, December 17, 2009 ª2009 Elsevier Inc. 513
Figure 1. Suppression of ISG Protein Induction in HCV-Infected Cells
(A) Persistently infected Huh-7 cells and JFH-1 full-length stable replicon cells were treated with different doses of IFNb as indicated in the figure. At various times
thereafter, the intracellular HCV RNA and GAPDH mRNA (for normalization) were quantified by RT-qPCR. Data are represented as mean ± average deviation;
n = 3. The results are representative of two independent experiments.
(B–D) Huh-7 cells were infected with JFH-1 virus at moi = 0.2, and at day 5 postinfection, uninfected () and infected (+) cells were treated for 16 hr with different
doses of IFNb.
(B) Quantification of the intracellular HCV RNA by RT-qPCR in total RNA isolated from HCV-infected or uninfected cells. GAPDH mRNA quantification was used
for normalization. Data are represented as mean ± average deviation; n = 3. The results are representative of three independent experiments.
(C) Analysis by western blotting of ISG (MxA and ISG15) and viral (NS5A and core) protein expression induced by IFNb in cell extracts of HCV-infected or unin-
fected cells. b-actin expression was examined as protein loading control. Each sample represents a pool of three replicas.
(D) Immunofluorescence analysis of MxA (in green) and viral E2 (in red) protein expression in uninfected and HCV-infected cells after IFNb treatment. The nuclei
were stained by Hoechst solution (blue). White arrows in HCV-infected panels point to cells with high MxA expression levels and with no or very low E2 staining.
These images are representative of three different experiments.
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proteins in infected cells.
RESULTS
HCV Infected Cells Are Less Responsive to Type I IFN
Than Are JFH-1 Full-Length Stable Replicon Cells
We examined the antiviral effect of type I IFN against HCV in
JFH-1 full-length stable replicon cells and persistently infected
cells by analyzing their intracellular HCV RNA content at various
times after IFNb treatment. As shown in Figure 1A, HCV RNA
levels were strongly reduced in JFH-1 stable replicon cells as
early as 24 hr after administration of doses as low as 1 U/ml of
IFN. In contrast, the intracellular HCVRNAcontent of persistently
infected cells was unchanged until 48 hr after administration of
100 U/ml of IFN. These results confirm previous reports demon-
strating the high susceptibility of HCV replicon systems to type I
IFN treatment (Guo et al., 2001) and illustrate that HCV-infected514 Cell Host & Microbe 6, 513–522, December 17, 2009 ª2009 Elsecells are quite significantly more resistant to IFN than stable
full-length replicon cells.
IFN-Stimulated Protein Induction Is Reduced
in HCV-Infected Cells
To understand the basis of the relative resistance of infected
cells to IFN, we examined the impact of HCV on the cellular
response to type I IFN by analyzing the accumulation of IFN-
induced antiviral effector proteins in infected and uninfected
Huh-7 cells. Huh-7 cells were infected with JFH-1 at low multi-
plicity of infection (moi = 0.2). Five days later, IFNb was added,
and cellular extracts were analyzed for HCV RNA and for ISG
(i.e., MxA and ISG15) and viral (i.e., NS5A and core) proteins
16 hr later by RT-qPCR and western blotting, respectively. As
shown in Figures 1B and 1C, IFNb had little or no impact on
intracellular HCV RNA and HCV core and NS5A protein levels
during the 16 hr of the experiment. However, HCV-infected
cells produced much less MxA and ISG15 protein than didvier Inc.
Figure 2. The Accumulation and Nucleocytoplasmic Distribution of
ISG mRNAs Are Normal in HCV-Infected Cells
Huh-7 cells were infected with JFH-1 virus at moi = 0.2. At day 5 postinfection,
uninfected andHCV-infected cells were treatedwith different doses of IFNb for
16 hr.
(A) Quantification of ISG (MxA, ISG15, IFIT1, and PKR) mRNA levels by
RT-qPCR in total RNA samples isolated from uninfected and HCV-infected
cells. GAPDH mRNA quantification from the same samples was used for
normalization. Results display the average fold induction for each ISG
mRNA relative to its expression level in untreated, uninfected Huh-7 cells.
Data are represented as mean ± average deviation; n = 3. The results are
representative of three independent experiments.
(B) Quantification of MxA, ISG15, and GAPDHmRNAs in the nuclear and cyto-
plasmic fractions of uninfected and HCV-infected cells. Results are displayed
as percentage of cytoplasmic versus total mRNA content for each sample.
Each bar in the graph corresponds to the mean ± average deviation; n = 3.
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Similar results were obtained when Huh-7 (Figure S1A available
online) or Huh-7.5.1 (Figure S1B) cells were infected at high
multiplicity of infection and treated with IFNb at 72 hr postinfec-
tion or when persistently infected Huh-7 cells were treated with
IFNb (Figure S1C) or IFNa (Figure S1D). In contrast, ISG protein
expression was strongly induced by IFNb in both Con-1 (geno-
type 1b) and JFH-1 (genotype 2a) full-length stable replicon
cells compared to their corresponding cured cells (Figure S1E),
underlining the differential IFN sensitivity of replicon and in-
fected cells. Collectively, these results indicate that HCV atten-
uates the expression of IFN-inducible proteins in infected Huh-7
cells.
Next, we analyzed the differences in ISG protein accumulation
observed in Figures 1C and S1 at the single-cell level by immu-
nofluorescence of uninfected and HCV-infected IFNb-treated
Huh-7 cells. Cells were fixed and costained for MxA (in green)
and viral E2 (in red) protein. As shown in Figure 1D, all IFNb-
treated uninfected cells displayed homogeneous MxA staining,
whereas only rare cells in the IFNb-treated infected cultures
were MxA positive (white arrows in Figure 1D), and these cells
were HCV E2 negative. In contrast, the HCV E2-positive (i.e., in-
fected) cells were MxA negative. Collectively, these results
confirm, at the single-cell level, that ISG protein expression is
attenuated in HCV-infected Huh-7 cells.
HCV Does Not Block Transcription or
Nucleocytoplasmic Transport of ISG mRNAs
The foregoing results could reflect defects at the levels of: IFN
signaling; ISG mRNA transcription, nucleocytoplasmic trans-
port, stability, and translation; or ISG protein stability. To deter-
mine whether HCV blocks either IFN signaling or ISG mRNA
transcription or stability, we treated HCV-infected and unin-
fected Huh-7 cells with different doses of IFNb and monitored
the ISG mRNA level 16 hr later by RT-qPCR. As shown in
Figure 2A and consistent with our previous results (Cheng
et al., 2006), all tested ISG mRNAs (MxA, ISG15, IFIT1, and
PKR) were induced in HCV-infected cells at least as much as
in uninfected cells, indicating that HCV does not suppress
type I IFN signaling or ISG mRNA transcription or stability in
infected Huh-7 cells. To determine whether HCV blocks the
nucleocytoplasmic transport of the ISG mRNAs, we compared
the cytoplasmic and nuclear levels of MxA, ISG15, and GAPDH
mRNA in uninfected and HCV-infected IFN-treated Huh-7 cells.
As shown in Figure 2B, HCV does not alter the nucleocytoplas-
mic distribution of these ISG mRNAs. Collectively, these results
demonstrate that HCV attenuates the induction of ISG proteins
posttranscriptionally in infected cells.
Global Cellular Protein Synthesis Is Reduced
in IFN-Treated HCV-Infected Cells
The lack of an effect on the steady-state content of ISG mRNA
(Figure 2) suggests that HCV could block the induction of ISG
proteins (Figure 1) at the translational level. To test that hypoth-
esis, metabolic pulse-labeling experiments were carried out. As
described in Figure 1, Huh-7 cells were inoculated with JFH-1 at
low multiplicity of infection (moi = 0.2), and 5 days later, infected
and uninfected cells were treated with different concentrations
of IFNb. Sixteen hours later, the cells were pulse labeled forCell Host &1 hr with 35S-Met, and cellular extracts were analyzed by electro-
phoresis and phosphorimaging. As shown in Figure 3, HCV had
little or no effect on global protein synthesis (compare lanes 1
and 2). Similarly, IFNb had no effect in uninfected Huh-7
(compare lane 1 with lanes 3, 5, 7, and 9). However, cellular
protein synthesis was clearly reduced in the IFN-treated HCV-
infected cells (compare lane 2 with lanes 6, 8, and 10), and this
was confirmed by quantitation of cellular protein radioactivity
after methanol-chloroform precipitation of the samples (middle
panel). Similar results were obtained when IFNa was used
instead of IFNb (Figure S2). Time of addition experiments
revealed that the impact of IFN on global protein synthesis in
HCV-infected cells increased as a function of time and the extent
of HCV infection (Table S1). In addition, these experiments also
revealed that HCV infection itself had a slight negative impactMicrobe 6, 513–522, December 17, 2009 ª2009 Elsevier Inc. 515
Figure 3. Global Cellular Protein Synthesis Is Inhibited in IFNb-
Treated HCV-Infected Cells
Huh-7 cells were infected with JFH-1 virus at moi = 0.2. At day 5 postinfection,
uninfected () and HCV-infected (+) cells were treated with different doses of
IFNb for 16 hr, after which the cultures were metabolically labeled for 1 hr with
35S-Met. Protein extracts prepared in RIPA buffer were quantified by BCA.
Equivalent amounts from each sample were analyzed by SDS-PAGE,
Coomassie staining (bottom), and autoradiography (top). The figure is repre-
sentative of two independent experiments with two replicas per sample. The
radioactivity present after methanol-chloroform (4:1) precipitation of each
sample was quantified, and the results were displayed as counts per minute
(cpm) per microgram of total protein (middle).
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these results suggest that HCV slightly reduces de novo protein
synthesis in infected Huh-7 cells, and this effect is greatly
enhanced in the presence of IFN. The mechanism responsible516 Cell Host & Microbe 6, 513–522, December 17, 2009 ª2009 Elsefor these interesting results was investigated in the following
experiments.
HCV Infection Triggers PKR and eIF2a Protein
Phosphorylation
Cellular protein synthesis is tightly regulated at the level of initia-
tion, elongation, and termination. The eukaryotic initiation factor
2 (eIF2) is a key regulator of translation initiation in multiple
settings, including viral infection (Hershey, 1991). When eIF2a
is phosphorylated by kinases such as PKR, PERK, GCN2, and
HRI, translation initiation and, therefore, protein synthesis is
inhibited (reviewed in Garcı´a et al., 2006). Kang et al. have
recently reported that transfection of replication-competent
HCV JFH-1 RNA induces PKR and eIF2a phosphorylation
(Kang et al., 2009). Given the inhibition of protein synthesis
that we observed during HCV infection (Table S1) and in IFN-
treated HCV-infected cells (compare lanes 6, 8, and 10 to lanes
5, 7, and 9 in Figure 3), we examined the phosphorylation status
of eIF2a and its kinases during HCV infection. Huh-7 cells were
infected at a high multiplicity of infection (moi = 3), and cellular
extracts were analyzed by western blotting at different times
after infection. As shown in Figure 4A, intracellular HCV RNA
expanded rapidly during the infection, and it was accompanied
by a corresponding increase in viral E2 (Figure 4C), NS5A (Fig-
ure 4B), and core (Figure S3A) protein accumulation, which,
collectively, reflect active viral replication via double-stranded
RNA (dsRNA) replicative intermediates (Figure 4C). Of interest,
HCV infection strongly triggered the phosphorylation of the
dsRNA-dependent protein kinase (PKR) and eIF2a proteins
(Figure 4B), but not PERK or GCN2 (Figure S3B), suggesting
that PKR is responsible for the observed eIF2a phosphorylation.
In addition, PKR and eIF2a proteins were also highly phosphor-
ylated in HCV-infected Huh-7.5.1 cells and in Huh-7 cells
that were treated with neutralizing IFNa/b receptor antibodies,
suggesting that HCV-induced PKR phosphorylation does not
reflect type I IFN induction in the infected cells (Figures S3C
and S3D).Figure 4. HCV Infection Triggers the Phos-
phorylation of PKR and eIF2a Proteins
Huh-7 cells were infected (+) or not () with JFH-1
d183 virus at moi = 3.
(A) At the indicated time points postinocculation,
total RNA was isolated from HCV-infected or unin-
fected cells, and the intracellular HCV RNA levels
werequantifiedbyRT-qPCR.GAPDHmRNAquan-
tification was used for normalization. Data are
represented as mean ± average deviation; n = 3.
(B) At the indicated time points, cellular extracts
were prepared in RIPA buffer, their protein content
was quantified by BCA, and the accumulation of
cellular eIF2a, phospho-eIF2a (p-eIF2a), PKR,
phospho-PKR (p-PKR), and viral NS5A proteins
was analyzed by western blotting. b-actin expres-
sion was examined as protein loading control. The
results displayed are representative of three inde-
pendent experiments.
(C) Cultures infected in parallel were fixed at the
indicated time points and processed for immuno-
fluorescence for the detection of viral E2 (in red) or
dsRNA (in green). The nuclei were stained by
Hoechst solution (blue).
vier Inc.
Figure 5. HCV Infection Strongly Enhances Phosphorylation of PKR
and eIF2a Proteins in IFNb-Treated Cells
Huh-7 cells were infected with JFH-1 virus at moi = 0.2. At day 5 postinfection,
uninfected () and infected (+) cells were treated for 16 hr with different doses
of IFNb. Total cellular protein in extracts prepared in RIPA buffer was quantified
by BCA. Equivalent amounts from each sample were subjected to western blot
analysis for the detection of viral core and cellular eIF2a, p-eIF2a, PKR, and
p-PKR proteins. b-actin expression was examined as protein loading control.
The figure is representative of two independent experiments with three
replicas per sample.
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was not surprising that global cellular protein synthesis slightly
decreased during HCV infection (Table S1). Nonetheless, the
HCV core (Figure S3A), E2, and NS5A (Figures 4C and 4B,
respectively) protein content increased progressively in the
infected cells despite the reduction in cellular protein synthesis,
indicating that HCV protein synthesis is relatively insensitive to
the inhibitory effects of phosphorylated eIF2a, as previously
reported (Robert et al., 2006; Shimoike et al., 2009; Terenin
et al., 2008).
HCV Increases PKR and eIF2a Phosphorylation
in IFN-Treated Cells
Although PKR expression is induced by IFN, its activation
requires binding to dsRNA and subsequent autophosphorylation
(Thomis and Samuel, 1993). To determine whether the inhibition
of global protein synthesis that we observed in IFN-treated HCV-
infected cells (Figure 3) was due to hyperphosphorylation of PKR
and eIF2a, uninfected and HCV-infected Huh-7 cells were
treated with a wide range of IFNb concentrations for 16 hr, at
which time cellular extracts were prepared and the levels of viral
core protein and cellular eIF2a and PKR proteins and their phos-
phorylated forms were determined by western blotting. As
shown in Figure 5, IFN had little or no effect on viral core and total
eIF2a protein levels. In contrast, IFN strongly induced the accu-
mulation of PKR protein, a well-known ISG (Samuel, 1991), in
uninfected cells. Importantly, PKR protein induction was greatly
attenuated in the infected cells, similar to the attenuated induc-
tion of MxA and ISG15 protein accumulation shown in Figure 1.
Nonetheless, reflecting the dsRNA content of the infected cells,
PKR phosphorylation and, therefore, eIF2a phosphorylation
were much more strongly induced in IFN-treated HCV-infected
cells than in uninfected cells.Cell Host &HCV Infection Kinetics Are Unaffected by
Downregulation of PKR Expression
As shown in Figures 4 and S3, HCV protein and RNA expansion
proceeded in parallel with the phosphorylation of PKR and eIF2a
in infected cells despite the fact that total protein and ISG protein
synthesis were suppressed (Table S1). To confirm the relative
insensitivity of HCV to translational regulation by phosphorylated
PKR, we examined the impact of PKR downregulation on the
kinetics and magnitude of HCV infection. We first generated
Huh-7 cells in which PKR expression was downregulated by
transduction with lentivirus vectors that express short hairpin
RNAs (shRNAs) that specifically target PKR. As controls, naive
Huh-7 cells and Huh-7 cells that were cotransduced with lenti-
virus vectors that express GFP and shRNAs specific against
GFP were used. After verifying that total PKR and GFP protein
content was downregulated (Figure S4A), naive, PKR- or GFP-
downregulated Huh-7 cells were infected with JFH-1 virus at
high multiplicity of infection (moi = 5), and the extracellular
infectivity and intracellular HCV RNA content were determined
at various times thereafter. The kinetics of both extracellular
infectivity (Figure 6A) and intracellular HCV RNA (Figure S4B) in
PKR-downregulated cells were virtually the same as in GFP-
downregulated or naive Huh-7 cells. These kinetic results indi-
cate that HCV infection is not altered by reduced levels of
PKR, indicating that HCV is resistant to the translational inhibi-
tory effects of the phosphorylated forms of PKR and eIF2a that
it induces during infection.
PKR Downregulation Restores ISG Protein Expression
in HCV-Infected Cells and Enhances the Antiviral Effect
of IFN
In view of the foregoing, we hypothesized that, by activating
PKR, HCV triggers the phosphorylation of eIF2a and, thereby,
inhibits the synthesis of interferon-stimulated antiviral proteins.
To demonstrate that HCV inhibits ISG protein synthesis by
inducing PKR activation, Huh-7 cells were transduced with the
same lentiviruses described in Figure 6A, and PKR- or GFP-
downregulated and control Huh-7 cells were infected at high
multiplicity of infection (moi = 5) 6 days later. At the peak of the
infection (70 hpi), the cells were treated with 100 U/ml of IFNb
for 20 hr when cellular extracts were prepared for protein anal-
ysis by western blotting. As shown in Figure 6B, MxA, ISG15,
and PKR protein expression was strongly induced by IFN in non-
transduced or GFP shRNA-transduced, HCV-uninfected Huh-7
cells (lanes 2 and 10, respectively), in contrast to HCV-infected
cells in which they were much less strongly induced (lanes 4
and 12), reflecting the corresponding phosphorylation of PKR
and eIF2a proteins. As expected, neither PKR, phospho-PKR,
nor phospho-eIF2a was detectable under any conditions in the
PKR-downregulated cells (lanes 9–12). In the absence of PKR,
however, the magnitude of IFN-stimulated MxA and ISG15
protein expression in HCV-infected cells was restored to the
level in uninfected cells (compare lanes 8 and 6, respectively)
without a corresponding change in mRNA (data not shown), sug-
gesting that the HCV-induced PKR and eIF2a phosphorylation
were responsible for the suppression of ISG protein accumula-
tion shown in Figures 1 and 6B (lanes 4 and 12). Of interest,
whereas the levels of viral core and NS5A proteins were not
altered by IFN in Huh-7 and GFP-downregulated cells, both viralMicrobe 6, 513–522, December 17, 2009 ª2009 Elsevier Inc. 517
Figure 6. PKR Downregulation Does Not Affect HCV Infection
Kinetics, Restores HCV-Induced ISG Protein Suppression, and
Enhances the Antiviral Effect of IFN
Huh-7 cells were transduced with lentiviral vectors expressing GFP and
shRNAs against GFP or PKR.
(A)PKR-,GFP-downregulated, andHuh-7cells, usedascontrols,were infected
with JFH-1 d183 virus at moi = 5, and the extracellular infectivity was deter-
mined at various times thereafter. Data are represented as mean ± average
deviation; n = 3. The graph is representative of three independent experiments.
(B) Transduced and control cells were infected (+) or not () with JFH-1 d183
virus at moi = 5. At 70 hpi, the cultures were treated (+) or not () with 100 U/ml
of IFNb for 20 hr, after which cellular extracts were prepared in RIPA buffer.
Equivalent amounts of total protein were analyzed by western blotting for
core, NS5A, MxA, ISG15, PKR, p-PKR, eIF2a, and p-eIF2a proteins. b-actin
expression was examined as protein loading control.
(C) HCV RNA present in samples generated in parallel was extracted and
analyzed by RT-qPCR. GAPDH mRNA quantification of the same samples
Cell Host & Microbe
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518 Cell Host & Microbe 6, 513–522, December 17, 2009 ª2009 Elseproteins were suppressed in IFN-treated PKR-downregulated
cells, suggesting that the antiviral effect of IFN is increased in
cells with reduced levels of PKR.
To further investigate the role of PKR downregulation on the
antiviral effect of IFN, infected GFP-, PKR-downregulated, and
Huh-7 cells were treated with 100 U/ml of IFNb, and intracellular
HCV RNA levels were determined by RT-qPCR 20 hr later. As
expected from the low-moi infection experiments shown in
Figure 1A, IFN treatment had minimal (10%–20%) impact on
the HCV RNA content of naive and GFP shRNA-transduced
Huh-7 cells (Figure 6C). In contrast, IFN treatment reduced the
HCV RNA content of PKR-deficient cells by 70%–80%, sug-
gesting that the increased ISG protein expression in those cells
(Figure 6B, lane 12) mediated the antiviral effects of IFN.
Of interest, as shown in Figure 7, IFN time of addition experi-
ments in infected PKR-downregulated and control Huh-7 cells
revealed a direct correlation between the degree of PKR phos-
phorylation and HCV resistance to IFN and an inverse correlation
between PKR phosphorylation and MxA protein accumulation,
used as a readout for ISG protein expression. Collectively, these
results suggest that HCV-induced PKR phosphorylation is
responsible for the reduced levels of ISG proteins in infected
cells and for the resistance of HCV to the antiviral effects of IFN.
DISCUSSION
One of the main characteristics of HCV is its tendency to persist
despite the massive type I ISG expression response that it
induces in the liver (Alter and Seeff, 2000; Hoofnagle, 2002; Lan-
ford et al., 2007; Su et al., 2002). This is consistent with the fact
that IFN monotherapy is ineffective in the vast majority of HCV-
infected patients (Deutsch and Hadziyannis, 2008; McHutchison
et al., 1998). Moreover, a large proportion of patients are also
resistant to treatment withmassive doses of pegylated interferon
plus ribavirin (Fried et al., 2002; Hadziyannis et al., 2004;
McHutchison et al., 1998; Miglioresi et al., 2003; Sjogren et al.,
2007). A desire to understand the molecular basis for the resis-
tance of HCV to the interferon-stimulated antiviral response
that it induces in the infected liver motivated the experiments
described in this report.
In this study, we compared the response of HCV-infected
and -uninfected Huh-7 cells to type I interferon in the in vitro
JFH-1 infection system in order to understand the mechanism(s)
whereby HCV resists IFN. We showed that IFN strongly induces
ISG mRNA transcription in HCV-infected cells, reaching even
higher levels than in uninfected cells, indicating that HCV does
not block IFN signaling. These results differ from the negative
impact of individually overexpressed HCV proteins on IFN-
induced Jak-Stat pathway activation and ISG mRNA transcrip-
tion (reviewed in Wohnsland et al., 2007), perhaps reflecting
the more physiological protein expression levels achieved in
the context of the complete viral life cycle in our studies.
However, the current results confirm previous observationswas used for normalization. IFN-treated samples are represented by gray
bars and untreated controls by black bars. The results are displayed as
mean ± average deviation; n = 3. Panels are representative of three indepen-
dent experiments with three replicas per sample.
vier Inc.
Figure 7. HCV Resistance to IFN Correlates with PKR Phosphoryla-
tion and Is Inversely Related to ISG Protein Expression
Huh-7 cells were transducedwith lentiviral vectors expressing shRNAs against
PKR, as indicated in Figure 6. Transduced and control cells were pretreated
with 100 U/ml of IFN (P) or remain untreated (the rest). After 16 hr, all of the cells
were infectedwith JFH-1 d183 virus atmoi = 3, and at the indicated times post-
infection, cells were treated with 100 U/ml of IFNb for 20 hr, after which cellular
extracts were prepared for RNA and protein analysis.
(A) The HCV RNA present in those samples was analyzed by RT-qPCR. The
quantification of GAPDH mRNA was used for normalization. Data are dis-
played as percentage of remaining HCV RNA in IFN-treated samples relative
to that in the untreated ones at each time point. Bars in the graph represent
the mean ± average deviation; n = 3. The graph is representative of two inde-
pendent experiments with three replicas per sample.
(B) Equivalent amounts of total protein from samples generated in parallel were
analyzed by western blotting for MxA and p-PKR protein detection. b-actin
expression was examined as protein loading control. Panels are representa-
tive of two independent experiments.
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element (ISRE) promoter in HCV-infected and -uninfected cells
(Cheng et al., 2006), and they are consistent with the strong
ISG mRNA induction observed in HCV-infected livers from natu-
rally infected humans (Alter and Seeff, 2000) and experimentally
infected chimpanzees (Hoofnagle, 2002; Lanford et al., 2007; Su
et al., 2002).
Unexpectedly, the current results demonstrate that not only
IFNb-, but also IFNa-induced, ISG protein expression is attenu-
ated in HCV-infected cells. Importantly, IFN time of addition
experiments revealed that maximal suppression of ISG protein
accumulation was achieved when IFN was added at the peak
of HCV infection rather than early in the infection, as previously
reported (Erickson et al., 2008; Kang et al., 2009), presumably
because early IFN addition inhibits HCV infection sufficiently to
prevent the induction of PKR phosphorylation. These resultsCell Host &suggest that a minimum level of HCV replication is needed to
trigger PKR phosphorylation and suppression of ISG protein
expression.
Because our results indicate that HCV does not block tran-
scription or nucleocytoplasmic transport of ISGmRNAs, we per-
formed pulse-labeling experiments to determine whether HCV
inhibits the translation or the stability of ISG proteins. Pulse-
labeling experiments demonstrated that HCV slightly inhibits
global cellular protein synthesis, that this inhibition is greatly
enhanced in IFN-treated cells (both IFNb and IFNa), and that
both effects occur in parallel with the strong phosphorylation
of PKR and eIF2a in HCV-infected cells. In agreement with these
results, Kang et al. have recently shown that electroporation of
a replication-competent HCV JFH-1 RNA genome triggered
the phosphorylation of PKR and eIF2a proteins in Huh-7 cells
(Kang et al., 2009). In contrast to these findings, others have
shown that the HCV NS5A and E2 proteins inhibit PKR activation
(Gale et al., 1997, 1998; Taylor et al., 1999) and mediate IFN
resistance in subgenomic replicon systems (Sumpter et al.,
2004). We suggest that these discrepancies probably reflect
intrinsic differences of the experimental systems used in each
study (e.g., genotype 1a and 1b replicons versus genotype 2a
infectious virus), given that we showed that the induction of
ISG proteins by IFN treatment is not suppressed in Con-1 and
JFH-1 full-length stable replicon cells. We suggest that the
results imply that replicon models do not represent the whole
spectra of viral-host interactions that occur during HCV infection
or that they reflect the elimination of phospho-PKR-inhibitable
clones during the replicon clonal selection process. Nonethe-
less, the results reported herein do not dispute the PKR-inacti-
vating potential of NS5A and E2. Indeed, the ability of HCV to
induce PKR phosphorylation in our system might have been
even stronger in the absence of the attenuating potential of
NS5A and E2. They do, however, argue against the hypothesis
that NS5A and E2 function as viral evasion proteins because
our results show that suppression of PKR phosphorylation
enhances the antiviral effect of IFN against HCV, at least in the
current JFH1 cell culture infection system.
PKR activation, through eIF2a phosphorylation and the inhibi-
tion of translation, has been shown to inhibit a variety of other
viral infections and to mediate some of the antiviral effects of
IFN (Garcı´a et al., 2006; Samuel, 2001). To counteract this
antiviral effect, many RNA viruses inhibit the activation of PKR
(Garcı´a et al., 2006). In contrast, HCV and Sindbis virus (a
member of the alphavirus family) strongly activate PKR and
eIF2a phosphorylation but have evolved eIF2a-independent
mechanisms to initiate translation (Robert et al., 2006; Shimoike
et al., 2009; Terenin et al., 2008; Ventoso et al., 2006). Consistent
with these observations, our results indicate that HCV expansion
is unaffected by reduced levels of PKR because downregulation
of PKR did not significantly alter HCV infection kinetics.
Importantly, IFN-mediated ISG protein expression was
restored if PKR protein production and, thus, PKR and eIF2a
phosphorylation were suppressed in HCV-infected cells. ISG
protein restoration correlated with an increase in the antiviral
effect of IFN, suggesting that the antiviral effects of IFN against
HCV are dependent on the expression of antiviral ISGs other
than PKR. The fact that HCV-IRES translation has been shown
to be relatively resistant to eIF2a phosphorylation (ShimoikeMicrobe 6, 513–522, December 17, 2009 ª2009 Elsevier Inc. 519
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(Koev et al., 2002; Terenin et al., 2008) compared to other viral
IRES and cap-dependent translation (Koev et al., 2002; Terenin
et al., 2008) makes the activation of a classical antiviral factor,
i.e., PKR, paradoxically a potential survival mechanism for
HCV because it blocks the expression of antiviral proteins
induced by IFN. This concept could have important therapeutic
implications because the administration of PKR inhibitors that
would prevent eIF2a phosphorylation could enhance the effec-
tiveness of IFN-based therapy by increasing the accumulation
of antiviral ISG proteins.
Clinical studies have shown that patients with high HCV load
are less responsive to IFN therapy than patients with lower viral
load (Fried et al., 2002; Manns et al., 2001). This is consistent
with our observation that the magnitude of ISG protein induction
is inversely related to the HCV content of IFN-treated cells. If
hepatic PKR and eIF2a phosphorylation also reflects the magni-
tude of HCV viral load in vivo, onewould expect the expression of
antiviral ISG proteins to be attenuated in those patients. This
hypothesis could be tested by analysis of the ISG protein content
of HCV-infected hepatocytes in interferon-treated HCV-infected
patients and chimpanzees in the future. It may also explain why
massive doses of interferon are required to terminate HCV infec-
tion in vivo and why most treated patients do not respond to
interferon therapy even when it is combined with ribavirin.
In summary, the current results indicate that HCV strongly
induces PKR phosphorylation, but it appears to be resistant
to translational inhibition by PKR. In contrast, HCV strongly
suppresses the ability of IFN to induce ISG proteins by inducing
hyperphosphorylation of PKR in the presence of IFN. Because
phosphorylated PKR triggers translational suppression of
cellular mRNAs but has little or no impact on the kinetics or
magnitude of HCV infection, our results suggest that, by inducing
PKR phosphorylation, HCV suppresses the translation of poten-
tially antiviral ISGs that would otherwise threaten its survival.
These findings may explain how HCV can thrive in the liver in
the face of a robust intrahepatic ISG mRNA response, i.e., by
suppressing translation of ISG proteins.
EXPERIMENTAL PROCEDURES
Biological Materials and Reagents
The origins of Huh-7 (Zhong et al., 2005), Huh-7.5.1 (Zhong et al., 2005), Huh-
7.5.1 subclone 2 (clone 2), and the full-length JFH-1 stable replicon cell line
(Gastaminza et al., 2008) and HEK293T (Graham et al., 1977) cells have
been described previously. All cells were maintained in DMEM (Cellgro; Medi-
atech, Herndon, VA) supplemented with 10% FBS (Cellgro), 10 mM HEPES
(Invitrogen, Carlsbad, CA), 100 units/ml penicillin, 100 mg/ml streptomycin,
and 2 mM L-glutamine (Invitrogen) in 5% CO2 at 37
C. The plasmid containing
the JFH-1 (Kato et al., 2003) genome was kindly provided by T. Wakita. Lenti-
viral vectors encoding short hairpin RNAs (shRNAs) targeting PKR and GFP
were commercially available (Sigma Aldrich, St. Louis, MO). Vectors encoding
compatible packaging proteins and VSV-G were provided by Inder Verma
(Salk Institute, La Jolla, CA). Rabbit polyclonal antibodies for the detection
of MxA, ISG15, PKR, and eIF2a proteins were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). The rabbit phospho-specific antibody against
PKR (pT446) was from Epitomics (Burlingame, CA), and phospho-eIF2a
(Ser51), -PERK (Thr980), and -GCN2 (Thr898) were from Cell Signaling Tech-
nology (Danvers, MA). For detection of dsRNA (K1 antibody from English &
Scientific Consulting Bt, Hungary), b-actin (Sigma Aldrich), and viral core
protein (Affinity BioReagents, Golden, CO), mouse monoclonal antibodies
were used. The recombinant human IgG anti-E2 and the MS5 anti-NS5A anti-520 Cell Host & Microbe 6, 513–522, December 17, 2009 ª2009 Elsebodies were provided by D. Burton (The Scripps Research Institute) and M.
Houghton (Chiron), respectively. The recombinant human IFNb-1a and
IFNa-2a were purchased from PBL InterferonSource (Piscataway, NJ) and
Thapsigargin from Sigma Aldrich. Protease and phosphatase inhibitors were
obtained from Roche (Indianapolis, IN).
Virus Techniques
The original JFH-1 virus was generated by transfection of an in vitro tran-
scribed full-length JFH-1 HCV RNA into Huh-7 cells as previously described
(Zhong et al., 2005). JFH-1 and high titer virus stocks of JFH-1 day 183 virus
(Zhong et al., 2006) were produced by inoculation of Huh-7 or highly suscep-
tible Huh-7.5.1 subclone 2 cells, respectively, at moi = 0.01, as described
before (Gastaminza et al., 2008).
Protein Analyses
For protein labeling, cultures were washed twice with warm PBS and labeled
for 1 hr at various times post-infection or after IFN treatment with 35S-met to
a final concentration of 200 mCi/ml. Total extracts were prepared in RIPA buffer
(150 mM NaCl, 50 mM Tris [pH = 8], 1% NP-40, 0.5% Deoxycholate, and 1%
SDS), and after protein quantification by BCA, equivalent amounts of total
protein per sample were processed by SDS-PAGE and autoradiography. For
the radioactivity quantification, equivalent amounts of total protein were
subjected to methanol:chloroform (4:1) precipitation. Precipitates were resus-
pended in RIPA buffer, and after addition of four volumes of MicroSpint20
(PerkinElmer, Waltham, MA), the radioactivity was measured in a TopCount-
NXT Scintillation Counter (PerkinElmer). The results were expressed as counts
per minute per microgram of total protein.
For immunofluorescence experiments, Huh-7 cells were either infected with
JFH-1 as indicated or maintained uninfected as controls. After 5 days, cells
were treated with different doses of IFNb for 16 hr. At this point, the cultures
were washed with PBS and fixed for 20 min with 4% paraformaldehyde at
room temperature for further processing by immunofluorescence as previ-
ously described (Zhong et al., 2005). Images were obtained using a Zeiss
fluorescence microscope.
For western blot analysis, cell extracts were prepared in RIPA buffer supple-
mentedwith protease and phosphatase inhibitors and, after protein quantifica-
tion by BCA, equivalent amounts of total protein for each sample were
separated by SDS-PAGE and transferred to Immobilon membranes. The
membranes were blocked for 1 hr at room temperature with PBS-5% milk
and incubated with the primary antibodies diluted in 0.5% milk-0.1% Tween
20 in PBS at room temperature, for varying periods of time, depending on
each antibody. After washing four times for 15 min with 0.1% Tween 20 in
PBS, the membranes were incubated with a dilution of goat-anti-rabbit or
anti-mouse IgG conjugated to horseradish peroxidase in 0.5% milk-0.1%
Tween 20 in PBS. After washing four times for 15 min with 0.1% Tween 20
in PBS, membranes were developed using the SuperSignal-West-Pico
or -Femto substrates purchased from Thermo Scientific (Rockford, IL).
RNA Analyses
Total RNA was extracted from the cells using the guanidinium isothiocyanate
extraction method (Zhong et al., 2005) after adding 20 mg of glycogen (Roche)
per sample as a carrier. ISG (MxA, ISG15, PKR, and IFIT1), HCV, and GAPDH
(as control) RNA levels weremeasured by reverse transcription real-time quan-
titative PCR (RT-qPCR) as described previously (Zhong et al., 2005) using the
primers listed in the Supplemental Data.
For nucleocytoplasmic fractionation, cell cultures were resuspended in
isotonic buffer (150 mM NaCl, 1.5 mM MgCl2, 10 mM Tris HCl, 0.25%
NP40-RNase inhibitors, and 1mMDTT [pH 8.5]), and the nuclei were separated
by centrifugation for 5 min at 3000 rpm at 4C. After an additional wash in the
same buffer, the supernatants were pooled as cytoplasmic fraction, and the
pellet was used as nuclear fraction. The extraction of RNA from the nuclear
fraction was carried out as indicated above for total RNA. RNA from the
cytoplasmic fractions was isolated by incubation with proteinase K (1 mg/ml)
in 100 mM NaCl, 50 mM Tris, HCl-5 mM EDTA, and 0.5% SDS (pH 7.5) buffer
for 1 hr at 37C, followed by extraction with acid phenol-chloroform, and was
recovered by ethanol precipitation. Quantification of MxA, ISG15, and GAPDH
mRNA content in nuclear and cytoplasmic fractions was carried out as
described above.vier Inc.
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shRNAs
Vesicular stomatitis virus glycoprotein (VSV-G)-pseudotyped lentiviral parti-
cles were produced in HEK293T cells by cotransfection of lentiviral vectors
encoding shRNAs (targeting PKR or GFP) or GFP protein together with plas-
mids encoding compatible packaging proteins and VSV-G, as described
previously (Dreux et al., 2007). At 48 hr posttransfection, cell supernatants
were collected, filtered through 0.45 mm filters, and used to transduce Huh-7
cells. Out of five different PKR shRNAs (Sigma), #5 was selected because of
its efficacy in downregulating PKR protein in the absence of cytotoxic effect
(measured by the classical MTT assay). Its sequence is available in the Supple-
mental Data. The shRNA vector specific for GFP was commercially available
as Mission eGFP shRNA Control Vector (Sigma).SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, four
figures, and one table and can be found with this article online at http://
www.cell.com/cell-host-microbe/supplemental/S1931-3128(09)00381-3.
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